Gallium nitrate

Drug Profile

Gallium nitrate

Alternative Names: Calstat; G 4544; G 4544a; Ganite; NSC 15200

Latest Information Update: 09 Mar 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA)
  • Developer Cystic Fibrosis Foundation; Emisphere Technologies; Genta (CEASED); University of Washington
  • Class Antihypercalcaemics; Antineoplastics; Calcium regulators; Heavy metals; Small molecules
  • Mechanism of Action Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Malignant hypercalcaemia
  • Discontinued Bone cancer; Infections; Non-Hodgkin's lymphoma; Osteitis deformans; Osteoporosis

Most Recent Events

  • 21 Apr 2010 Pharmacokinetics data from a preliminary clinical trial in Cystic-fibrosis associated respiratory tract infections released by Genta
  • 13 Jan 2010 Preclinical pharmacodynamics data in Osteoporosis released by Genta
  • 03 Jun 2008 Interim pharmacokinetics data from a phase I trial presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top